about
Characterization of the imprinted polycomb gene L3MBTL, a candidate 20q tumour suppressor gene, in patients with myeloid malignanciesOncogenetics and minimal residual disease are independent outcome predictors in adult patients with acute lymphoblastic leukemia.Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1Evaluation of candidate control genes for diagnosis and residual disease detection in leukemic patients using 'real-time' quantitative reverse-transcriptase polymerase chain reaction (RQ-PCR) - a Europe against cancer program.A cooperative microRNA-tumor suppressor gene network in acute T-cell lymphoblastic leukemia (T-ALL).Interlaboratory development and validation of a HRM method applied to the detection of JAK2 exon 12 mutations in polycythemia vera patients.TET2 mutations are associated with specific 5-methylcytosine and 5-hydroxymethylcytosine profiles in patients with chronic myelomonocytic leukemia.Acute myeloid leukemia is propagated by a leukemic stem cell with lymphoid characteristics in a mouse model of CALM/AF10-positive leukemia.Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936.Vector integration is nonrandom and clustered and influences the fate of lymphopoiesis in SCID-X1 gene therapy.Unique long non-coding RNA expression signature in ETV6/RUNX1-driven B-cell precursor acute lymphoblastic leukemia.Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia.Establishing the transcriptional programme for blood: the SCL stem cell enhancer is regulated by a multiprotein complex containing Ets and GATA factors.Novel activating JAK2 mutation in a patient with Down syndrome and B-cell precursor acute lymphoblastic leukemia.Virological and molecular characterisation of a new B lymphoid cell line, established from an AIDS patient with primary effusion lymphoma, harbouring both KSHV/HHV8 and EBV viruses.DEK-CAN molecular monitoring of myeloid malignancies could aid therapeutic stratification.Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.FLT3 and MLL intragenic abnormalities in AML reflect a common category of genotoxic stress.Imatinib combined with induction or consolidation chemotherapy in patients with de novo Philadelphia chromosome-positive acute lymphoblastic leukemia: results of the GRAAPH-2003 study.Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.CALM-AF10+ T-ALL expression profiles are characterized by overexpression of HOXA and BMI1 oncogenes.Age-related phenotypic and oncogenic differences in T-cell acute lymphoblastic leukemias may reflect thymic atrophy.Complex MLL rearrangements in t(4;11) leukemia patients with absent AF4·MLL fusion alleleThe MLL recombinome of acute leukemiasImatinib and methylprednisolone alternated with chemotherapy improve the outcome of elderly patients with Philadelphia-positive acute lymphoblastic leukemia: results of the GRAALL AFR09 studyAssociation of a Duodenal Follicular Lymphoma and Hereditary Nonpolyposis Colorectal CancerProspective multicentric molecular study for poor prognosis fusion transcripts at diagnosis in adult B-lineage ALL patients: the LALA 94 experienceSuccessful treatment with imatinib mesylate in a case of chronic myeloproliferative disorder with a t(5;12)(q33;p13.1) without eosinophiliaThe CALM-AF10 fusion is a rare event in acute megakaryoblastic leukemiaDetection of the MPL W515L mutation in bone marrow core biopsy specimens with essential thrombocythemia using the TaqMan assayIgH/TCR rearrangements are common in MLL translocated adult AML and suggest an early T/myeloid or B/myeloid maturation arrest, which correlates with the MLL partnerHOXA cluster deregulation in T-ALL associated with both a TCRD-HOXA and a CALM-AF10 chromosomal translocationPAX5 P80R mutation identifies a novel subtype of B-cell precursor acute lymphoblastic leukemia with favorable outcome
P50
Q24317211-7C3C384E-493F-42CD-8B60-6C1126884D5EQ27852997-E6B3E397-2E0D-4A8B-B04F-8CBE1542FE5EQ28290118-76E1B774-1197-4ECF-89B0-459DA60A7061Q31012437-C86C969F-4466-4694-8689-DF07E4CB479DQ31016573-CE41D2F7-9271-4B3C-A1E7-23528AD479AEQ33609532-0C6C9C85-C7E9-42CF-9156-902A03D89C03Q34157339-04681C53-B68C-461F-91AB-78D5FB9388E6Q34580828-851A2D0E-1581-4078-8B63-D5744644E749Q35606345-A63C5D0D-A45D-4280-BDE4-BA82B30E48D4Q35916142-CB9148CC-180C-49B5-8B6A-77B650130374Q37687468-C6820F74-E1C0-4C08-A216-123855487930Q39485109-2A80173D-085F-455F-9AB0-31DF60559C58Q39647389-62BF560E-E0E8-4EC2-9DFC-4CE22D30242CQ40215071-420E6DD5-FCD6-4977-AFFC-FDCF2BF4FC5BQ40877025-3D4F695B-B089-4A5A-8637-85E75B019E1CQ43729633-CD7BF58E-4A66-48CF-B6E8-E8553F5DED4DQ43963780-28B485F0-C93E-49E8-A2C0-1FBD7BB25A46Q47854939-2FD6E023-2399-44A1-A9FB-A3A39D9DBE7DQ54574746-71056E64-80EF-4B4E-8739-4424FDF8CB52Q54613497-0E80C13B-264C-44F9-BDBB-8CF653DE1D9AQ54648219-73A13832-4247-42F4-B75A-E0D53F8CB42BQ54723450-EBB7D188-D9E0-46E4-A9D0-16F574A79172Q56965961-D9386427-36FF-4032-98F7-C775EFB7355EQ56965972-2191FDB3-ED67-4569-BA6B-DCFD20331D61Q56997440-29514DE9-0C5C-466F-A34C-3FF9519C6396Q58408696-742BFF1D-65A4-4F87-A54D-8A2B6A4470CFQ61053580-A3B976AF-16A0-439B-AD12-8F6BCF61AA06Q80180365-E6BBA4EE-BB46-492D-A862-2764282BE938Q80568643-B68FD2BB-E353-44AC-A5C0-866F1B33531DQ81340628-2EE4C749-675A-495D-9B4A-1FAB562ABC7FQ81521498-C456B32A-4036-4911-AE20-36AD5B559CFAQ83007216-EE80B1F1-9E30-43BD-A86C-5B713B975ED4Q90226951-76DACFC7-615A-4809-BF3C-C9CFE52AB1B1
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Eric Delabesse
@ast
Eric Delabesse
@en
Eric Delabesse
@es
Eric Delabesse
@nl
type
label
Eric Delabesse
@ast
Eric Delabesse
@en
Eric Delabesse
@es
Eric Delabesse
@nl
altLabel
Eric DELABESSE
@en
prefLabel
Eric Delabesse
@ast
Eric Delabesse
@en
Eric Delabesse
@es
Eric Delabesse
@nl
P1053
I-5221-2016
P106
P31
P496
0000-0002-0928-0753